Navigation Links
TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
Date:6/25/2008

ic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the potential for tezampanel and NGX426 as treatments for migraine and other forms of chronic pain such as neuropathic pain as well as muscle spasticity and rigidity secondary to spinal cord trauma, stroke and multiple sclerosis. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether any preclinical studies or clinical trials conducted in the future, will prove successful, and if successful, whether the results can be replicated. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company Contact: Media Contact:

Paul Schneider David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x125 212-845-4271

pschneider@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact:

Rhonda Chiger

Rx Communications

917-322-2569

rchiger@rxir.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
2. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
3. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
4. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
5. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
6. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
7. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
8. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... -- Sigma-Aldrich Corporation (NASDAQ: SIAL ... company, today announced the opening of its ... Cell Culture Technical Center in Singapore.  Located at ... support to meet customer needs, leveraging the Company,s ... Technical Center will significantly enhance our ability to ...
(Date:4/16/2015)... -- A drug commonly taken to prevent seizures in epilepsy ... (MS), according to a study released today that will be ... in Washington, DC , April 18 to ... MS experience at some point in their life a condition ... from the eye to the brain gets inflamed," said study ...
(Date:4/16/2015)... , April 16, 2015 Today, Kenneth C. ... & Co., Inc., was elected chairman of the Board of ... Board meeting, PhRMA,s president and CEO John J. Castellani ... 2016.  New Officers Elected to PhRMA Board ... succeeds Ian C. Read , chairman and CEO of ...
Breaking Medicine Technology:Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 3Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 4Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 5Epilepsy Drug May Preserve Eyesight for People with MS 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5
(Date:4/17/2015)... Washington, DC (PRWEB) April 17, 2015 ... the HHT Diagnoses and Treatment Act HR 1849 in ... improve diagnosis rates and treatment for patients with the ... introduced in the past, would be the first to ... diagnoses and appropriate treatment of hereditary hemorrhagic telangiectasia. This ...
(Date:4/17/2015)... April 17, 2015 Testosterone treatment ... class of prescription medications increases the likelihood that ... or other life-threatening cardiovascular event continue to mount ... Court, Northern District of Illinois. According to an ... Panel on Multidistrict Litigation (JPML) on April 15th, ...
(Date:4/17/2015)... Connie Casad, M.D., a well-known and respected gynecologist, ... years of practice experience in Dallas, Texas, has announced ... for her patients with the availability of a reader’s ... with a brief synopsis on each for her patients. ... providing this service, Dr. Casad said, “Furnishing a researched ...
(Date:4/17/2015)... has released a new blog post explaining the dangers of ... insurance rates . , Falling asleep at the wheel ... big impact on auto insurance prices. The premiums will go ... The newly released blog post talks more about drowsiness at ... It is now possible to find low cost car insurance ...
(Date:4/17/2015)... April 17, 2015 According to the ... estimated 50 million Americans suffer from all types of ... and eye allergies. Thanks to comprehensive allergy testing that’s ... caremedurgentcare.com ), there’s now a way to get recommended ... , “Allergy triggers, or allergens, can vary by region ...
Breaking Medicine News(10 mins):Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 3Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 4Health News:Connie Casad, M.D. Provides Patients Recommended List of Wellness Books on Website 2Health News:Accidents Caused By Sleeping at The Wheel Can Increase Auto Insurance Costs 2Health News:CareMed Urgent & Primary Care Now Offering Comprehensive Allergy Testing 2Health News:CareMed Urgent & Primary Care Now Offering Comprehensive Allergy Testing 3
... , WEDNESDAY, May 25 (HealthDay News) -- This ... "Don,t Fry Day," a time for skin-safety experts to remind ... Melanoma, the potentially deadly form of skin cancer, is the ... according to the U.S. Environmental Protection Agency (EPA) and the ...
... the FASEB Journal ( http://www.fasebj.org ) shows that ... maximizing the effects of exercise. Specifically, the report shows that ... six weeks, when compared to carbohydrate drinks. Additionally, this study ... as 20 grams of protein. "It is ...
... less-than-optimal levels of vitamin D who lose more than 15 ... levels of this fat-soluble nutrient, according to a new study ... vitamin D is generally lower in persons with obesity, it ... for the link between obesity and diseases such as cancer, ...
... As the use of oral chemotherapy continues to rise, researchers ... properly take the cancer-fighting medication, a significant clinical problem that ... of adherence needs to be addressed by the health care ... the study that is published in the May edition of ...
... WEDNESDAY, May 25 (HealthDay News) -- Science has shown that ... mice to monkeys live longer. But can such a ... those extra years be healthy, happy ones? Recent research ... calorie intake have lower core body temperatures than those who ...
... announced an agreement with two non-profit organizations to ... rare blood cancers. The cooperative research and ... commitment to move therapies for rare blood cancers ... can eventually be commercialized. The agreement is among ...
Cached Medicine News:Health News:Skin Cancer Foes Declare May 27 'Don't Fry Day' 2Health News:Protein drinks after exercise help maintain aging muscles 2Health News:Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women 2Health News:Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women 3Health News:Many patients fail to properly take oral chemo, leading to complications 2Health News:Could 'Extreme' Low-Cal Diets Bring Longer, Healthier Life? 2Health News:Could 'Extreme' Low-Cal Diets Bring Longer, Healthier Life? 3Health News:NIH and non-profits sign research and development agreement 2
... standards set by the new SZ61 and ... "Comfort View eyepiece design and the accessible, ... fatiguing than ever before. The compact design ... field as well as clarity, detail, and ...
The modular, high-end stereomicroscope; meets even the most critical demands in research and quality control provides high-contrast images with excellent depth of field and color fidelity...
A compact stereomicroscope that is immediately ready for operation and extremely easy to use. Focused on the essential performance features, the Stemi DV4 design concept provides optimum utility....
10:1 Zoom Ratio - The parallel optical system of the SMZ-1000 has a 10:1 zoom with clickstops at 1X intervals. It features a zoom range of 0.8X to 8.0X and total magnification (depending on eyepieces...
Medicine Products: